Zack Rosenbloom

Investment Research Director at Gaingels

Zack Rosenbloom is the Investment Research Director at Gaingels, a position he has held since February 2023. Prior to this role, he served as the Investment Research Manager from June 2022 to February 2023 and as a Research Operations Associate from September 2021 to June 2022, where he was responsible for managing deal flow and preparing investment memos for syndication.

He has a diverse background in investment research and operations, having co-founded a startup called Bidversity and worked as a Rare Disease Research Associate at Pfizer. His educational background includes a Bachelor of Science in Cellular and Molecular Biology and Management and Legal Studies in Business from Tulane University, along with an Applied Data Science course from MIT.1

Experience

Investment Research Director at Gaingels (February 2023 - Present)

Investment Research Manager at Gaingels (June 2022 - February 2023), Research Operations Associate at Gaingels (September 2021 - June 2022), Co-Founder & Chief Operating Officer at Bidversity (June 2020 - September 2021), Rare Disease Research Associate at Pfizer (November 2019 - July 2020), Medical Project Manager at Trois Prime Inc. (February 2019 - November 2019), Business Development and Implementation Strategist at ReSuture (February 2019 - July 2019), Rare Disease Medical Affairs Intern at Pfizer (May 2018 - October 2018), Business Analyst at Tefen Management Consulting (May 2017 - September 2017)

Education

Bachelor of Science - BS, Cellular and Molecular Biology at Tulane University (2015 - 2019), Applied Data Science Course in Data Processing at Massachusetts Institute of Technology (2021), Bachelor of Science - BS, Management and Legal Studies in Business at Tulane University (2015 - 2019), Study Abroad Semester, Biology/Biological Sciences at King's College London (2017 - 2018), Oncology and Cancer Biology Non-Credit Summer Class at Emory University (2014)